Get the Stockscreener App
366.29
1.42%
-5.29
Pre-market:
366.29
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $366.29, with a volume of 2.82M.
It is down -1.42% in the last 24 hours and up +7.21% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$371.58
Open:
$373.97
24h Volume:
2.82M
Relative Volume:
1.07
Market Cap:
$197.69B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
25.47
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+0.80%
1M Performance:
+7.21%
6M Performance:
+10.86%
1Y Performance:
+22.81%
1-Day Range:
$361.72
$378.54
1-Week Range:
$353.95
$378.54
52-Week Range:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
366.29 | 200.54B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,179.11 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.04 | 601.73B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.49 | 449.45B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.50 | 315.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.76 | 291.42B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Decker Wealth Management LLC Purchases New Position in Amgen Inc. $AMGN - MarketBeat
Bessemer Group Inc. Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
AlTi Global Inc. Cuts Stock Position in Amgen Inc. $AMGN - MarketBeat
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? - The Motley Fool
FY2026 EPS Estimates for Amgen Lowered by Erste Group Bank - MarketBeat
Amgen stock trades steadily as oncology and cardiovascular pipeline supports long term growth - ad-hoc-news.de
Amgen stock steadies as investors digest recent earnings and pipeline updates - ad-hoc-news.de
Amgen stock holds support as investors weigh earnings - ad-hoc-news.de
Valley Wealth Managers Inc. Reduces Stock Position in Amgen Inc. $AMGN - MarketBeat
Mediolanum International Funds Ltd Buys 7,075 Shares of Amgen Inc. $AMGN - MarketBeat
Swiss National Bank Buys 105,080 Shares of Amgen Inc. $AMGN - MarketBeat
5,891 Shares in Amgen Inc. $AMGN Bought by Independent Financial Group LLC - MarketBeat
Amgen stock trades steady as investors digest Repatha growth and oncology pipeline - ad-hoc-news.de
AIA Group Ltd Grows Stake in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) RBC Capital Markets Global Healthcare Conference 2025 Summary - Quartr
Amgen stock trades steady as oncology and obesity pipeline shapes investor focus - ad-hoc-news.de
Amgen stock trades steadily as oncology pipeline and recent revenue gains frame investor focus - ad-hoc-news.de
Amgen stock holds steady as earnings and guidance frame the outlook - ad-hoc-news.de
Amgen stock trades steady as recent earnings and drug pipeline shape outlook - ad-hoc-news.de
John G Ullman & Associates Inc. Sells 6,675 Shares of Amgen Inc. $AMGN - MarketBeat
Modera Wealth Management LLC Sells 4,769 Shares of Amgen Inc. $AMGN - MarketBeat
Illinois Municipal Retirement Fund Has $5.38 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Lowered by California Public Employees Retirement System - MarketBeat
Amgen Inc. $AMGN Holdings Decreased by Bartlett & CO. Wealth Management LLC - MarketBeat
Atlas Wealth LLC Has $25.50 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Earnings Buzz Builds, Is The Stock Already Overvalued? - simplywall.st
Amgen stock edges higher as investors weigh recent revenue growth and obesity drug opportunity - ad-hoc-news.de
ETFs Investing in Amgen Inc. Stocks - TradingView
Amgen stock edges higher as osteoporosis drug backbone and strong cash generation support valuation - ad-hoc-news.de
Erste Group Bank Analysts Lower Earnings Estimates for Amgen - MarketBeat
SteelPeak Wealth LLC Acquires 20,118 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock trades steady as revenue growth and pipeline updates shape investor view - ad-hoc-news.de
Assetmark Inc. Purchases 15,719 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock trades steadily as recent earnings and pipeline progress shape sentiment - Ad Hoc News
Amgen Inc (AMGN) Stock Up 3.7% but GF Value Says Overvalued -- G - GuruFocus
Amgen stock advances after cardiovascular data and solid Q1 2026 growth - ad-hoc-news.de
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Wealthfront Advisers LLC Boosts Position in Amgen Inc. $AMGN - MarketBeat
D.A. Davidson & CO. Trims Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Bank of New York Mellon Corp - MarketBeat
(AMGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Amgen stock holds steady as biotech pipeline and US revenue base anchor long-term story - Ad Hoc News
Amgen’s Tablet Recalls Test Its Quality Controls and Manufacturing Ambitions (AMGN) - simplywall.st
Livforsakringsbolaget Skandia Omsesidigt Purchases 10,752 Shares of Amgen Inc. $AMGN - MarketBeat
Principal Financial Group Inc. Increases Stock Position in Amgen Inc. $AMGN - MarketBeat
AMG National Trust Bank Has $4.59 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset - MedCity News
Amgen Colo. Win May Chill States' Push To Cap Drug Prices - Law360
Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen - 24/7 Wall St.
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):